The Biotech Growth Stock Total Debt
| BIOG Stock | 878.00 3.00 0.34% |
The Biotech Growth fundamentals help investors to digest information that contributes to Biotech Growth's financial success or failures. It also enables traders to predict the movement of Biotech Stock. The fundamental analysis module provides a way to measure Biotech Growth's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biotech Growth stock.
Biotech | Total Debt |
The Biotech Growth Company Total Debt Analysis
Biotech Growth's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Biotech Growth Total Debt | 47.08 M |
Most of Biotech Growth's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, The Biotech Growth is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Biotech Net Debt
Net Debt |
|
Based on the latest financial disclosure, The Biotech Growth has a Total Debt of 47.08 M. This is 99.88% lower than that of the Capital Markets sector and 99.16% lower than that of the Financials industry. The total debt for all United Kingdom stocks is 99.11% higher than that of the company.
Biotech Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biotech Growth's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biotech Growth could also be used in its relative valuation, which is a method of valuing Biotech Growth by comparing valuation metrics of similar companies.Biotech Growth is currently under evaluation in total debt category among its peers.
Biotech Growth ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Biotech Growth's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Biotech Growth's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Biotech Fundamentals
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.93 % | ||||
| Operating Margin | 0.98 % | ||||
| Current Valuation | 359.66 M | ||||
| Shares Outstanding | 31.52 M | ||||
| Shares Owned By Insiders | 0.72 % | ||||
| Shares Owned By Institutions | 29.36 % | ||||
| Price To Book | 0.74 X | ||||
| Price To Sales | 3.03 X | ||||
| Revenue | 80.35 M | ||||
| Gross Profit | (32.42 M) | ||||
| EBITDA | 74.76 M | ||||
| Net Income | 74.6 M | ||||
| Total Debt | 47.08 M | ||||
| Book Value Per Share | 10.79 X | ||||
| Cash Flow From Operations | (4.24 M) | ||||
| Earnings Per Share | 2.07 X | ||||
| Beta | 0.5 | ||||
| Market Capitalization | 261.93 M | ||||
| Total Asset | 411.42 M | ||||
| Retained Earnings | (965 K) | ||||
| Net Asset | 411.42 M |
About Biotech Growth Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze The Biotech Growth's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biotech Growth using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of The Biotech Growth based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Biotech Stock Analysis
When running Biotech Growth's price analysis, check to measure Biotech Growth's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotech Growth is operating at the current time. Most of Biotech Growth's value examination focuses on studying past and present price action to predict the probability of Biotech Growth's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotech Growth's price. Additionally, you may evaluate how the addition of Biotech Growth to your portfolios can decrease your overall portfolio volatility.